Under construction – not a live service
Sign in
Taking people in United StatesPhase 2

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

Key facts

Where
Baton Rouge, Birmingham, Canton, Chapel Hill, Chicago, Cromwell, Dallas, Fountain Valley, Los Angeles, Missouri City, New Brighton, New Orleans, New York, Omaha, Plainfield, Portland, San Antonio, Sandy Springs, Smyrna, and St Louis, United StatesSee the 20 sites
Phase
Phase 2

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 79 years old?

Source: NCT07783542, who can take part

Where in United States

  • Baton Rouge, LouisianaHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Birmingham, AlabamaHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Canton, MichiganHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Chapel Hill, North CarolinaHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Chicago, IllinoisHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Cromwell, ConnecticutHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Dallas, TexasHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Fountain Valley, CaliforniaHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Los Angeles, CaliforniaHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Missouri City, TexasHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • New Brighton, MinnesotaHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • New Orleans, LouisianaHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • New YorkHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Omaha, NebraskaHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Plainfield, IndianaHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Portland, OregonHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • San Antonio, TexasHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Sandy Springs, GeorgiaHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • Smyrna, TennesseeHospital not named in the registryContact: Oruka Investigative SiteTaking people
  • St Louis, MissouriHospital not named in the registryContact: Oruka Investigative SiteTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Oruka Therapeutics, Inc.
Trial code
NCT07783542
Record updated
29 October 2026
Original description
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.Read full original descriptionShow less

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa

This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.

Inclusion: Has signs and symptoms of HS for at least 6 months; Has HS lesions present in ≥ 2 distinct anatomic areas, one of which must be at least Hurley Stage II or III; Has a history of inadequate response to systemic antibiotic treatment for HS, exhibited recurrence of HS symptoms after discontinuation of systemic antibiotics for HS, demonstrated intolerance to systemic antibiotics for HS, or has a contraindication to systemic antibiotics for HS.

Exclusion: Presence of any other active skin disease or condition that may interfere with the assessment of HS; Diagnosis or suspected diagnosis of autoimmune diseases or inflammatory conditions other than HS.

ClinicalTrials.gov NCT07783542